Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 28 articles:
HTML format



Single Articles


    February 2024
  1. GEBHART G, Piccart M, Mankoff D
    Molecular Imaging in Breast Cancer: Martine Piccart and Geraldine Gebhart Talk with David Mankoff About 2 Generations of Research.
    J Nucl Med. 2024 Feb 8:jnumed.124.267461. doi: 10.2967/jnumed.124.267461.
    PubMed    


  2. JACENE H, Dietsche E, Specht J
    The Current and Future Roles of Precision Oncology in Advanced Breast Cancer.
    J Nucl Med. 2024 Feb 1:jnumed.122.264882. doi: 10.2967/jnumed.122.264882.
    PubMed     Abstract available


  3. GONDRY O, Caveliers V, Xavier C, Raes L, et al
    Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
    J Nucl Med. 2024;65:178-184.
    PubMed     Abstract available


    January 2024
  4. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
    First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
    J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
    PubMed     Abstract available


    December 2023
  5. MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al
    Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
    J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938.
    PubMed     Abstract available


    November 2023
  6. CHEN L, Zheng S, Chen L, Xu S, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.
    J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079.
    PubMed     Abstract available


  7. GEBHART G
    (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
    J Nucl Med. 2023;64:1697-1698.
    PubMed    


    September 2023
  8. ALTENA R, Af Buren S, Tran T, Axelsson R, et al
    HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101.
    PubMed    


  9. SEBAN RD
    Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490.
    PubMed    


    August 2023
  10. HENNESSY MA, Leal JP, Huang CY, Solnes LB, et al
    Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
    J Nucl Med. 2023 Aug 31:jnumed.123.265853. doi: 10.2967/jnumed.123.265853.
    PubMed     Abstract available


  11. MOHR P, van Sluis J, Providencia L, van Snick JH, et al
    Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for (89)Zr-Trastuzumab.
    J Nucl Med. 2023 Aug 3:jnumed.123.265621. doi: 10.2967/jnumed.123.265621.
    PubMed     Abstract available


    July 2023
  12. ALHUSEINALKHUDHUR A, Lindman H, Liss P, Sundin T, et al
    Human Epidermal Growth Factor Receptor 2-Targeting [(68)Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.
    J Nucl Med. 2023 Jul 13:jnumed.122.265364. doi: 10.2967/jnumed.122.265364.
    PubMed     Abstract available


    June 2023
  13. BROWN EL, Shmuel S, Mandleywala K, Panikar SS, et al
    Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    J Nucl Med. 2023 Jun 29:jnumed.122.265172. doi: 10.2967/jnumed.122.265172.
    PubMed     Abstract available


  14. WATABE T, Naka S, Tatsumi M, Kamiya T, et al
    Initial Evaluation of [(18)F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
    J Nucl Med. 2023 Jun 2:jnumed.123.265486. doi: 10.2967/jnumed.123.265486.
    PubMed     Abstract available


    May 2023
  15. SEBAN RD, Champion L, Bellesoeur A, Vincent-Salomon A, et al
    Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.
    J Nucl Med. 2023 May 25:265434. doi: 10.2967/jnumed.123.265434.
    PubMed    


    April 2023
  16. DONOHOE KJ, Carroll BJ, Chung DKV, Dibble EH, et al
    Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema.
    J Nucl Med. 2023;64:525-528.
    PubMed     Abstract available


    March 2023
  17. ULANER GA, Mankoff DA, Clark AS, Fowler AM, et al
    Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16alpha-(18)F-Fluoro-17beta-Fluoroestradiol.
    J Nucl Med. 2023;64:351-354.
    PubMed     Abstract available


    January 2023
  18. FENG Y, Meshaw R, Zhao XG, Jannetti S, et al
    Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose (211)At-Labeled Anti-HER2 Single-Domain Antibody Fragment.
    J Nucl Med. 2023;64:124-130.
    PubMed     Abstract available


    November 2022
  19. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    PubMed     Abstract available


  20. BACKHAUS P, Burg MC, Asmus I, Pixberg M, et al
    Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264871. doi: 10.2967/jnumed.122.264871.
    PubMed     Abstract available


    October 2022
  21. VOGSEN M, Harbo F, Jakobsen NM, Nissen HJ, et al
    Response monitoring in metastatic breast cancer - a prospective study comparing (18)F-FDG PET/CT with conventional CT.
    J Nucl Med. 2022 Oct 7. pii: jnumed.121.263358. doi: 10.2967/jnumed.121.263358.
    PubMed     Abstract available


    September 2022
  22. MORAWITZ J, Sigl B, Rubbert C, Bruckmann NM, et al
    Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on (18)F-FDG PET/MRI and machine-learning.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264138. doi: 10.2967/jnumed.122.264138.
    PubMed     Abstract available


    August 2022
  23. SHIN J, Parker MFL, Zhu I, Alanizi A, et al
    Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264284. doi: 10.2967/jnumed.122.264284.
    PubMed     Abstract available


  24. SINGARAVELU I, Spitz H, Mahoney M, Dong Z, et al
    Antiandrogen Therapy Radiosensitizes Androgen Receptor-Positive Cancers to (18)F-FDG.
    J Nucl Med. 2022;63:1177-1183.
    PubMed     Abstract available


    June 2022
  25. ZHOU R, Choi H, Cao J, Pantel A, et al
    (18)F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264152. doi: 10.2967/jnumed.122.264152.
    PubMed     Abstract available


    May 2022
  26. OKAZAWA H
    ER Imaging for Estrogen-Related Tumors Is Bothersome but Useful.
    J Nucl Med. 2022;63:700-701.
    PubMed    


    December 2021
  27. SEBAN RD, Richard C, Nascimento-Leite C, Ghidaglia J, et al
    Absolute lymphocyte count after COVID-19 vaccination is associated with vaccine-induced hypermetabolic lymph nodes on (18)F-FDG PET/CT: a focus in breast cancer care.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.263082. doi: 10.2967/jnumed.121.263082.
    PubMed     Abstract available


  28. MORTIMER JE, Bading JR, Frankel PH, Caroll M, et al
    Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262940. doi: 10.2967/jnumed.121.262940.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.